Key words: phencyclidine -excitatory amino acid antagonists -catalepsy -2-amino-5-phosphonovalerate -pigeons This study presents experimental evidence for the mediation of a behavioral effect of phencyclidine-like drugs by inhibition of neurotransmission at excitatory synapses utilizing N-methyl-aspartate (NMA) receptors by showing that DL-2-amino-5-phosphonovalerate, a selective NMA antagonist, produces phencyclidine-like catalepsy in pigeons. This finding suggests the possibility that other behavioral actions of phencyclidine-like substances may be mediated in a similar fashion.
Phencyclidine (PCP), a major drug of abuse, has anesthetic actions and produces effects that resemble schizophrenia. The mechanism of action of PCP-like drugs has not been established, although specific binding sites in brain have been identified that appear to be pharmacologically relevant 4"7"9. PCP-like drugs selectively antagonize excitation of spinal neurons by N-methylaspartate (NMA) 1"2. Therefore, the behavioral effects of PCP-like drugs might result from reduced neurotransmission at excitatory synapses utilizing NMA receptors in higher centers of the central nervous system. Until now, this proposed explanation of the behavioral effects of PCP-like drugs is based exclusively on electrophysiological findings. In the present study, we have made an initial attempt to evaluate experimentally the possible involvement of NMA receptors in the mediation of behavioral actions of PCP-like drugs. If PCP-like drugs produce behavioral effects primarily through antagonism at excitatory synapses utilizing NMA receptors, drugs that are known to antagonize electrophysiological effects of NMA should produce PCP-like behavioral effects. DL-2-Amino-5-phosphonovalerate (AP5) is a potent and highly selective NMA antagonist 8. A procedure for the measurement of catalepsy in pigeons, suitable for studying PCP-like activity of compounds, has been described 5. PCP-induced catalepsy was shown to be pharmacologically specific and stereoselective, as evidenced by the observation that pentobarbital fails to induce catalepsy and that catalepsy is induced by the ( + )-isomers but not by the ( -)-isomers of PCPlike drugs. The catalepsy test was used to investigate possible PCP-like effects of the NMA-antagonist, AP5.
The subjects were 10 experimentally naive White Carneaux pigeons (weighing between 450-550 g), which were housed individually, with food and water freely available. A chronic, indwelling guide cannula was implanted under anesthesia with the tip directly into the lateral ventricle 3. Cannula patency was assessed by a radiographic method 3. Five pigeons were tested after intracerebroventricular (i.c.v.) injections (10/al/pigeon) of PCP (free base, dissolved in sterile water; pH 6-8; Warner-Lambert/ParkeDavis, Ann Arbor). The other 5 pigeons were tested with AP5 (dissolved in 1 N NaOH, to which sterile water was added; pH 6-8; Tocris Chemicals, Buckhurst Hill, England). Presence or absence of catalepsy (defined as loss of fighting, without head-drop and without eye closure) was assessed at successive time-intervals after each injection. Tests of different doses were separated by 48 h.
Catalepsy was induced dose-and time-dependently by i.c.v, administration of PCP (Fig. 1 , upper panels). AP5 produced catalepsy that had each of the signs of PCP-induced catalepsy noted above, and these effects were also dose-and timedependent (Fig. 1, upper lefthand panel, lower  panel) . AP5 was more potent and had a longer duration of action than PCP. The mean threshold dose (average of the lowest dose which produced catalepsy at 15 min postinjection in each pigeon) of PCP was 2.7 + 0.4 (S.E.M.)#mol/pigeon (ca. 1.3 mg/kg). The mean threshold dose of PCP, when administered i.m., has been shown to be 1.5 + 0.3 mg/kg 5, suggesting that PCP is equipotent when given i.c.v, or i.m. The mean threshold dose of AP5 was 0.5 + 0.2 #mol, about 5 times smaller than the mean threshold dose of PCP (Student's t = 4.17, df = 8, P < 0.01). The mean duration of catalepsy (average of duration of catalepsy in each pigeon) was 33 + 7min after 4.1 #mol of PCP and was about 5 times longer (i.e. 183 + 83 min) after 1 #mol ofAP5 (t = 1.97, df = 8, P < 0.10).
That AP5 had the capacity to produce catalepsy of a form comparable to PCP was striking. This finding shows that a drug previously identified as an NMA antagonist appears to have PCP-like behavioral effects and adds behavioral evidence to the electrophysiological observations of a coincidence of PCP-agonist and NMA-antagonist effects of a variety of drugs. Structure- activity studies are necessary to study whether this PCP-like behavioral action of AP5 is dependent upon the NMA-antagonist properties of AP5. However, the present result makes viable the hypothesis stated above that catalepsy and, perhaps, other behavioral effects of PCP-like substances, may be mediated by inhibition of neurotransmission at excitatory synapses utilizing NMA receptors. There is a strong association between PCP-induced catalepsy in pigeons, PCPlike discriminative stimulus effects in pigeons 6, and PCP-like anesthesia. Therefore, NMA antagonists might have PCP-like anesthetic actions. 
